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Introduction  
       Non-alcoholic fatty liver disease 
(NAFLD) is a chronic liver disease 
which refers to the presence of hepatic 
steatosis without significant intake of 
alcohol. Non-alcoholic fatty liver 
disease develops in a variety of forms 
from reversible simple steatosis to 
non-alcoholic steatohepatitis (NASH), 
which if  left unchecked can progress 
to liver fibrosis, cirrhosis and even 
develop into hepatocellular carcinoma 
(Mells et al., 2014).  
     NAFLD is thought to be 
nonthreatening, but with progression 
over several years could lead to NASH.  
A strong link between obesity and 
NASH has been shown. In addition to 
obesity, insulin resistance (type II 
diabetes mellitus), and hyperlipidemia 
all common components of metabolic 
syndrome, is frequently associated 
with NAFLD (Nseiri, Mograbi, & Ghali, 
2012). 
      If NAFLD goes undetected and 
progresses, steatohepatitis a serious 
inflammation of the liver can occur.   
Steatosis is a term used to describe any 
condition that allows fat to deposit 
within the interstitial spaces of an 
organ. Steatohepatitis comes in two 
forms. alcohol-related and non-
alcoholic related. The distinction of 
hepatic steatosis lays in excessive 
alcohol consumption verses little to no 
alcohol consumption.  
 
Signs & Symptoms 
The symptoms of both types of 
steatosis are the same, but treatments 
for each are very different. In NASH 
treatment consist of focus on other 
lifestyle changes such as diet, exercise, 
and weight control.  
• Early, asymptomatic 
• Late, general malaise and fatigue, 
unintentional weight loss, loss of 
appetite, nausea, confusion, poor 
judgement or trouble 
concentrating 
• Diagnosis made based on 
abnormal liver enzymes and 
further testing  
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NAFLD affects a considerable number of the general population and is 
closely associated with metabolic syndrome. Although simple fatty liver disease 
is seen in about one-third of the population, it is a relatively benign disease, but 
is associated with an increased mortality rate (House et al., 2013).  Of these 
individuals NASH seems to occur in approximately 3% of the US population but 
may be found in more than 25% of obese persons (House et al., 2013). 
Due to the consequences of the disease a uniform prevention and 
screening for associated risk factors should be followed. Ongoing research and 
large clinical control trials are being investigated to provide healthcare 
providers and patients with more targeted treatment modalities. Finally, 
studies on the multifaceted pathogenesis of NASH may not only improve our 
understanding of the mechanisms involved in NASH progression, but also may 
lead to innovative therapeutic strategies to treat this condition. Prevention is 
key to reducing the harmful outcomes of NAFLD to NASH.  
 
 
 
 
 
Conclusion  
Significance of Pathophysiology  
Nurse practitioners have the ability to reach the general population, and 
teach community members preventive methods in decreasing his/her risk for 
developing NASH. An important part of health care today is screening and 
surveillance by way of patient education. Nurse practitioners are at the 
forefront of prevention and promoting healthy lifestyle changes. 
There is not one specific test to diagnosis a patient with NASH. A through 
history and review of associated health risk must be assessed. Patients whom 
are obese with insulin resistance (type 2 DM), high cholesterol  (triglycerides), 
and metabolic syndrome are at risk for developing NASH.  If risk factors are 
identified additional testing such as  blood test including liver function test, 
abdominal ultrasound, CT scan, and liver biopsy my be indicated for a 
definitive diagnosis. When further evaluation shows no apparent reason for 
liver disease (such as medications, viral hepatitis, or excessive use of alcohol) 
and when x rays or imaging studies of the liver show fat, NASH is suspected. 
NASH is almost always a chronic condition and associated with obesity, and 
type II diabetes.  Currently no specific therapies for NASH exist. Prevention and 
management consist of  decrease in alcohol consumption, diet, weight loss and 
exercise programs. Improved glucose control, along with weight management 
has shown marked improvements in aminotransferase levels (Perseghin, 
2011). In addition to improved liver function, tight glucose control will 
decrease the effects of hyperlipidemia, and hypertension.  
Underlying Pathophysiology 
    
Figure 1. Pathophysiology of NASH. From “Role of Obesity and Lipotoxicity 
in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and 
Clinical Implications”, by K. Cusi. http://www.gastrojournal.org, Copyright 
[2012] AGA Institute. Published by Elsevier Inc. 
       Although NASH has become more 
common, its underlying cause is still not 
clear. The progression of NAFLD to 
NASH is multifactorial and includes both 
environmental and genetic factors. The 
major feature of NASH is fat in the liver 
along with damaged hepatocytes from 
inflammation. Three definitive 
characteristics have been identified in 
the process of NASH;  
• insulin resistance/ 
hyperinsulinemia  
• resistance release of toxic 
inflammatory proteins by fat cells 
(cytokines)  
• oxidative stress inside liver cells 
("Nonalcoholic Steatohepatitis," 
2006).  
        Purposed pathophysiology from 
steatosis to steatohepatitis to eventual 
fibrosis of the liver is based on what is 
called a “two hits” hypothesis. Vonghia, 
Michielsen, & Francque (2013), “The 
initial “two hits” hypothesis described 
insulin resistance as “first hit” that leads 
to hepatic steatosis and is followed by a 
“second hit” driven by oxidative stress, 
which in turn leads to the development 
of steatohepatitis and fibrosis”(p. 
19868). 
  
Vonghia, Michielsen, & Francque (2013), 
A key role in the development of insulin 
resistance is played by altered lipid 
metabolism that generates lipid 
intermediates, which in turn are able to 
activate different kinases, such as the 
mammalian target of rapamycin 
(mTOR), the inhibitor of κB-kinase (IKK), 
the c-Jun N-terminal kinase (JNK) and 
the novel protein kinase C (nPKC). The 
activation of these kinases has a negative 
feedback on proximal insulin signaling, 
contributing to insulin resistance and to 
a hyperinsulinemic state that further 
increases de novo liponeogenesis, 
hepatic lipid accumulation and disease 
progression. (p. 19868)  
      The “second hit” developed in this 
hypothesis is related to the abundance of 
oxidative stress found in the liver with 
NASH. Improper clearance of pro-
oxidative species manifest as reactive 
oxidative stress (ROS). Pro-oxidative 
stress is known to interfere with nucleic 
acid, protein, and cell membrane 
function (Vonghia et al., 2013).  
       More importantly the role of ROS, 
Tariq, Green, & Hodson (2014), these 
species can initiate lipid peroxidation by 
targeting polyunsaturated fatty acids 
(FAs), resulting in the formation of 
highly reactive aldehyde products, such 
as 4-hydroxy-2-nonenal (4-HNE) and 
malondialdehyde (MDA). These reactive 
lipid derivatives have the potential to 
amplify intracellular damage by 
mediating the diffusion of ROS/RNS into 
the extracellular space thus causing 
tissue damage. (p.181)  
       Over the past several years, the 
incidence of NAFD has been on a steady 
rise. The rise of detected cases is directly 
related to the increase incidence of 
obesity. NAFLD is rapidly becoming the 
most common liver disease worldwide. 
Twenty to thirty percent of the general 
population in Western counties has 
NAFLD (Gitto, Vitale, Villa, & Andreone, 
2015). About 2% to 3% of the general 
populations have non-alcoholic 
steatohepatitis (NASH), which may 
progress to liver cirrhosis and 
hepatocellular carcinoma (HCC) (Nseiri 
et al., 2012).  
       In recent research the role of both 
innate and adaptive immunity is 
demonstrating a strong link to the 
pathogenesis of NASH. For example 
Kupffer cells (KC), known to contribute 
to innate immunity are the first 
responding cells to hepatocyte injuries, 
leading to tumor necrosis factor-α (TNF-
α) production, chemokine induction, and 
monocyte recruitment all contributing to 
pro-inflammatory responses of the 
hepatocytes (Vonghia et al., 2013). As for 
adaptive immunity, an imbalance in 
subtypes of T lymphocytes, such as 
CD4+/CD8+ cells potentiate cytotoxic T 
cell release further promoting 
inflammation and destruction of 
hepatocytes (Vonghia et al., 2013). The 
above are just two of the many roles 
both  adaptive and innate immunity play 
in the development of NASH. Continued 
research and clinical trials provide a 
promising future of pharmacologic 
treatments in this disorder.  
Normal liver tissue (1) normal hepatocyte and (2) normal central vein in; B) Fat 
droplet deposition (the arrow ↑) extending in up to 66% indicating steatosis 
grade 2  C) NASH with (1) fat deposition, (2) portal mononuclear cell deposition 
indicating inflammation and (3) portal fibrosis in D) loss of normal hepatic 
architecture with cirrhotic nodule surrounded by fibrous tissue (the arrow ↑) 
 
Figure 2.Photomicroscopic pictures of isolated liver tissue. From “Serum 
Resistin,Vaspin and Chemerin in Rats with Non Alcoholic Fatty Liver Disease: 
Correlation with Metabolic and Haemostatic Parameters”, by K. EL-Kashish, 
http://article.sapub.org/10.5923.j.medicine.20140304.02.html. Copyright [2014] 
Scientific & Academic Publishing. 
